Showing 1 - 5 results of 5 for search '(( significantly ((larger decrease) OR (small decrease)) ) OR ( significant cause decrease ))~', query time: 0.40s Refine Results
  1. 1

    Image 2_Allergen immunotherapy using recombinant Culicoides allergens improves clinical signs of equine insect bite hypersensitivity.tif by Anneli Graner (19759464)

    Published 2024
    “…</p>Results<p>In the first treatment year, the decrease in average IBH lesion score was significantly larger in the AIT compared to the placebo group, with 67% of the AIT group and 25% of the placebo horses reaching >50% improvement of the average IBH lesion score. …”
  2. 2

    Image 1_Allergen immunotherapy using recombinant Culicoides allergens improves clinical signs of equine insect bite hypersensitivity.jpeg by Anneli Graner (19759464)

    Published 2024
    “…</p>Results<p>In the first treatment year, the decrease in average IBH lesion score was significantly larger in the AIT compared to the placebo group, with 67% of the AIT group and 25% of the placebo horses reaching >50% improvement of the average IBH lesion score. …”
  3. 3

    Image 1_Safety profile and efficacy of secukinumab in the treatment of autoimmune myasthenia gravis: a single-center retrospective study.jpeg by Shuangmei Zhang (1807303)

    Published 2025
    “…These findings highlight IL-17 inhibition as a promising targeted strategy for MG. Limitations include small sample size and retrospective design, warranting validation in larger randomized trials.…”
  4. 4

    Data Sheet 1_Safety profile and efficacy of secukinumab in the treatment of autoimmune myasthenia gravis: a single-center retrospective study.pdf by Shuangmei Zhang (1807303)

    Published 2025
    “…These findings highlight IL-17 inhibition as a promising targeted strategy for MG. Limitations include small sample size and retrospective design, warranting validation in larger randomized trials.…”
  5. 5

    PDLB - Balance Sheet by Nguyen Linh (19516642)

    Published 2024
    “…It built out management capabilities for a much larger bank, and is currently seeing decreasing Q/Q non-interest cost, while assets and interest income are growing nicely.…”